文献速递呼吸危重症与机械通气

气道压力释放通气在小儿急性呼吸窘迫综合征中的随机对照试验

Airway Pressure Release Ventilation in Pediatric Acute Respiratory Distress Syndrome. A Randomized Controlled Trial.
PubMed 文献 · Am J Respir Crit Care Med · 2018-01-01

该开放标签平行随机对照试验在15张床ICU纳入1月至12岁符合改良柏林定义ARDS患儿,比较APRV与常规低潮气量通气对无呼吸机天数的影响。因中期分析显示干预组死亡率更高,试验在入组50%(52例)时终止,无呼吸机天数两组差异无统计学意义(P=0.23),28天全因死亡率APRV组53.8% vs 对照组26.9%(RR 2.0,95%CI 0.97-4.1;Fisher P=0.089)。

要点

  • APRV作为小儿ARDS初始通气策略,28天死亡率呈高于常规低潮气量通气的趋势。
  • 两组无呼吸机天数差异无统计学意义(P=0.23),试验因干预组死亡率更高提前终止。
  • APRV组平均气道压更高、自主呼吸更多且氧合早期改善,但需谨慎解读死亡风险。

核心结论

  • APRV作为小儿ARDS的主要通气策略,与常规低潮气量通气相比死亡风险呈升高趋势(多因素校正RR 2.02,95%CI 0.99-4.12;P=0.05)。

研究设计与样本

  • 开放标签、平行设计随机对照试验,在15张床ICU开展,纳入1月至12岁符合改良柏林定义的ARDS患儿。
  • 排除气漏、颅内压增高、自主呼吸努力差、慢性肺病、ARDS诊断超过24小时或通气超过72小时者。
  • 采用非分层可变区组随机化,计划在入组50%时进行期中分析,随访至入组后180天或死亡。
  • 试验在入组50%(52例)时因干预组死亡率更高而终止。

主要发现

  • 无呼吸机天数两组差异无统计学意义(P=0.23)。
  • 28天全因死亡率APRV组53.8%,对照组26.9%(RR 2.0,95%CI 0.97-4.1;Fisher精确P=0.089)。
  • APRV组平均气道压更高、自主呼吸更多且氧合早期改善。

关键数值与推荐

  • 主要结局无呼吸机天数两组差异无统计学意义(P=0.23)。
  • 28天全因死亡率APRV组53.8% vs 对照组26.9%(RR 2.0,95%CI 0.97-4.1;Fisher精确P=0.089)。
  • 多因素校正死亡风险比APRV vs 常规低潮气量通气为2.02(95%CI 0.99-4.12;P=0.05)。

临床怎么用

  • 小儿ARDS以APRV作为初始通气策略需谨慎,因死亡风险呈升高趋势且试验提前终止。
  • 临床决策应结合本试验局限性,不应将APRV常规替代低潮气量通气用于小儿ARDS。

局限性

  • 试验在入组50%(52例)时提前终止,样本量小。
  • 为开放标签设计,可能存在偏倚。
  • 作者指出解读结果时应考虑研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Although case series describe benefits of airway pressure release ventilation (APRV), this mode of ventilation has not been evaluated against the conventional low-tidal volume ventilation (LoTV) in children with acute respiratory distress syndrome (ARDS). OBJECTIVES: To compare the effect of APRV and conventional LoTV on ventilator-free days in children with ARDS. METHODS: This open-label, parallel-design randomized controlled trial was conducted in a 15-bed ICU. Children aged 1 month to 12 years satisfying the modified Berlin definition were included. We excluded children with air leaks, increased intracranial pressure, poor spontaneous breathing efforts, chronic lung disease, and beyond 24 hours of ARDS diagnosis or 72 hours of ventilation. Children were randomized using unstratified, variable-sized block technique. A priori interim analysis was planned at 50% enrollment. All enrolled children were followed up until 180 days after enrollment or death, whichever was earlier. MEASUREMENTS AND MAIN RESULTS: The trial was terminated after 50% enrollment (52 children) when analysis revealed higher mortality in the intervention arm. Ventilator-free days were statistically similar in both arms (P = 0.23). The 28-day all-cause mortality was 53.8% in APRV as compared with 26.9% among control subjects (risk ratio, 2.0; 95% confidence interval, 0.97-4.1; Fisher exact P = 0.089). The multivariate-adjusted risk ratio of death for APRV compared with LoTV was 2.02 (95% confidence interval, 0.99-4.12; P = 0.05). Higher mean airway pressures, greater spontaneous breathing, and early improvement in oxygenation were seen in the intervention arm. CONCLUSIONS: APRV, as a primary ventilation strategy in children with ARDS, was associated with a trend toward higher mortality compared with the conventional LoTV. Limitations should be considered while interpreting these results. Clinical trial registered with www.clinicaltrials.gov (NCT02167698) and Clinical Trials Registry of India (CTRI/2014/06/004677).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Lalgudi Ganesan S, Jayashree M, Chandra Singhi S, et al. Airway Pressure Release Ventilation in Pediatric Acute Respiratory Distress Syndrome. A Randomized Controlled Trial. Am J Respir Crit Care Med. 2018. PMID: 29641221. doi:10.1164/rccm.201705-0989OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。